Comparative Pharmacology
Head-to-head clinical analysis: EFFEXOR XR versus PRISTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFEXOR XR versus PRISTIQ.
EFFEXOR XR vs PRISTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It potently inhibits the reuptake of serotonin and norepinephrine, and weakly inhibits dopamine reuptake. It has no significant affinity for muscarinic, histaminergic, or alpha1-adrenergic receptors.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It binds to the serotonin transporter (SERT) and norepinephrine transporter (NET), inhibiting reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations.
75 mg orally once daily; may increase by 75 mg/day increments every 4-7 days to max 225 mg/day.
50 mg orally once daily, with or without food; may increase by 50 mg every 7 days to a maximum of 100 mg once daily; maximum dose is 100 mg/day (some studies up to 400 mg/day but not recommended).
None Documented
None Documented
Venlafaxine: 3-7 hours (short, requires extended-release formulation for once-daily dosing); active metabolite O-desmethylvenlafaxine: 9-13 hours (contributes to overall clinical effect). Steady-state achieved within 3 days.
Desvenlafaxine: ~11 hours (range 8-15 h); supports once-daily dosing
Renal: approximately 87% as metabolites (including venlafaxine, O-desmethylvenlafaxine, and other minor metabolites) and ≤5% as unchanged drug. Biliary/fecal: minimal (about 2%).
Renal: 87% (45% desvenlafaxine unchanged, 42% as metabolites); biliary/fecal: minimal (<1%)
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant